Project Grant R03CA286532
Award Date
8/5/24
Completion Date
7/31/26
Dollars Obligated
$151K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
The Medical University of South Carolina (MUSC) was awarded a $2,718,000 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) for the period of September 1, 2022 through August 31, 2025. The grant will fund research to characterize metallothionein genes which are commonly suppressed in 70% of high-grade serous ovarian cancers. The researchers will develop models to suppress all 11 metallothionein genes and...
The National Cancer Institute (NCI) awarded a $560,297 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Icahn School of Medicine at Mount Sinai. The grant, with a project period from September 1, 2024 to August 31, 2029, will fund research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The research aims to determine the molecular drivers of the ONFSCS and their role in CRC progression and treatment resistance, as well as...
This Project Grant award of $695,797 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports a multi-disciplinary research program focused on discovering new tumor antigens and T-cell receptors (TCRs) for the treatment of platinum-resistant high-grade serous ovarian carcinoma (HGSOC). The award aims to leverage innovative multi-omic technologies, including long-read RNA sequencing and immunopeptidomics, to uncover cancer-specific protein isoforms that can...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant funding will support research to determine the role of key proteins like RAD52, HELQ, and POLQ in the backup repair of DNA double-strand breaks within homologous recombination deficient (HRD) cancers. The researchers aim to evaluate the relative contribution of these proteins to...
The National Cancer Institute (NCI) awarded a $158,020 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, awarded on August 18, 2025, supports research to investigate the role of mutagenic DNA repair pathways, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. Specifically, the project aims to (1) study persistence mechanisms in BRCA1/2-mutant cancer...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) totaling $180,632.00 to the University of Pittsburgh to study methods for inhibiting breast cancer metastasis. The key objectives of this initiative are to: Discover and validate compounds that can effectively block the engulfment of mesenchymal stem cells (MSCs) by breast cancer cells, as this engulfment process has been linked to increased tumor aggressiveness and metastatic potential. The...
This federal Project Grant award, with a total funding amount of $122,032.00, was provided by the National Cancer Institute (NCI) under its Cancer Research Manpower (CFDA 93.398) program. The award, titled "Dissecting the Contribution of Mis-Splicing in Cancer Phenotypes Through Multi-Omic Single-Cell Approaches," will be performed by Weill Medical College of Cornell University. The research aims to explore the role of aberrant splicing in cancer cell heterogeneity and its potential as...
This $612,288 Project Grant award from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program supports research into the role of elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche for high-grade serous ovarian cancer (HGSOC). The award was made on December 11, 2024 to the University of Wisconsin System, with an ultimate completion date of November 30, 2029. The research aims to advance understanding of the fundamental biological...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $107,948 to The Johns Hopkins University to advance the development of a liquid biopsy screening test for early detection of ovarian cancer. The project aims to expand bioinformatics approaches to study repeat elements in cell-free DNA, develop sensitive and specific liquid biopsy assays for ovarian cancer detection, and characterize genomic changes to repeat elements during...